# Cetuximab Plus Paclitaxel as First Line for Recurrent and/or Metastatic SCCHN: Real World Data.

> **NCT04672772** · — · COMPLETED · sponsor: **Grupo Español de Tratamiento de Tumores de Cabeza y Cuello** · enrollment: 531 (actual)

## Conditions studied

- Squamous Cell Carcinoma of the Head and Neck

## Interventions

- **DRUG:** Cetuximab
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT04672772
- **Lead sponsor:** Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-18
- **Primary completion:** 2022-01-17
- **Final completion:** 2022-01-17
- **Target enrollment:** 531 (ACTUAL)
- **Last updated:** 2022-03-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04672772

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04672772, "Cetuximab Plus Paclitaxel as First Line for Recurrent and/or Metastatic SCCHN: Real World Data.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04672772. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*